A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
Key facts
- Where
- Debrecen, Kaposvár, Szolnok, Szombathely és Veszprém, MagyarországSee the 5 sites
- Phase
- 2. fázis
Where in Magyarország
- University of DebrecenDebrecen, MagyarországNo longer taking part
- Somogy Megyei Kaposi Mór Oktató KórházKaposvár, MagyarországNo longer taking part
- Allergo-Derm Bakos KftSzolnok, MagyarországNo longer taking part
- University Teaching Hospital MarkusovszkySzombathely, MagyarországNo longer taking part
- Medmare Bt.Veszprém, MagyarországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly & Co.
- Trial code
- EU 2022-502888-38-00
- Record updated
- 2026. július 1.
- Original description
To compare the efficacy of LY3454738 versus placebo as measured by EASI-75 in the treatment of biologic-and-small-molecule—naïve participants with moderate-to-severe Atopic DermatitisRead full original descriptionShow less
J4E-MC-IMMB: A Master Protocol for Randomized, Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis; J4E-MC-FR01: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of LY3454738 in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis
To compare the efficacy of LY3454738 versus placebo as measured by EASI-75 in the treatment of biologic-and-small-molecule—naïve participants with moderate-to-severe Atopic Dermatitis
Inclusion: Have active atopic dermatitis for over a year and include the following:; EASI score ≥ 12 at first dosing visit; vIGA-AD score ≥3 at first dosing visit; Have ≥10% of BSA involvement (per EASI BSA) at first dosing visit; Have little improvement with topical medicines.
Exclusion: Have any prior skin infections requiring treatment with topical corticosteroids; Have history of psoriasis; Have other infections such as Hepatitis B or C; Known allergy to study drug or any components to formulation or history of drug hypersensitivity reactions.